Journal Mobile Options
Table of Contents
Vol. 117, No. 4, 2007
Issue release date: May 2007
Acta Haematol 2007;117:221–225

Refractory Anaemia with Excess of Blasts in Transformation Re-Evaluated with the WHO Criteria: Identification of Subgroups with Different Survival

Breccia M. · Latagliata R. · Carmosino I. · Gentilini F. · D’Elia G.M. · Levi A. · Natalino F. · Frustaci A. · De Cuia M.R. · Alimena G.
Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


One of the major changes suggested by the World Health Organization (WHO) classification with respect to the French-American-British (FAB) proposal for myelodysplastic syndromes (MDS) was to lower the bone marrow (BM) blast count from 30 to 20%, thus eliminating the refractory anaemia with excess of blasts in transformation (RAEB-t) category. However, a general consensus has not been reached, and several authors still retain RAEB-t as an MDS sub-entity. We re-evaluated our series of 74 patients classified as RAEB-t according to the FAB criteria by stratifying them into two subsets: patients with at least 5% peripheral blast (PB) cells but with BM blasts <20% (group I) and patients with BM blastosis between 20 and 30% and PBs <5% (group II). We found differences among the two groups regarding sex, haematological parameters at presentation (white blood cell and neutrophil counts, haemoglobin level) and frequency of infectious episodes during the course of disease. We did not find differences as to the frequency of acute myeloid leukaemia transformation, but a significant difference was evidenced as to survival (9.3 vs. 16 months in group I vs. group II, respectively; p = 0.02). Furthermore, at our institution, we compared the RAEB-t group I patients who, based on >5% PBs, should be included in the RAEB-II category according to the WHO criteria, with a group of 98 patients who were diagnosed as RAEB-II according to the WHO criteria. The findings showed that the aggregation of these two subsets appeared inappropriate, because patients of the two groups showed different clinical features and rates of acute transformation. In conclusion, the RAEB-t entity according to the FAB criteria, although including heterogeneous clinical patient subsets, should more likely be considered as an advanced stage of MDS, rather than a true acute myeloid leukaemia.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189–199.
  2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD: World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clinic Oncol 1999;17:3835–3849.
  3. Bennett JM: World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 2000;72:131–133.
  4. Ohyashiki K, Nishimaki J, Shoji N, Miyazawa K, Kimura Y, Ohyashiki JH: Re-evaluation of refractory anaemia with excess blasts in transformation. Leuk Res 2001;25:933–939.
  5. Strupp C, Gattermann N, Giagounidis A, Aul C, Hildebrandt B, Haas R, Germing U: Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals. Leuk Res 2003;27:397–404.
  6. An international system for human cytogenetic nomenclature (1985) ISCN (1978). Report of the Standing Committee on Human Cytogenetic Nomenclature. Cytogenet Cell Genet 1985;21:309–409.
  7. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D: Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985;59:425–433.
  8. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S, Irriguible D, San Miguel JF: Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989;74:395–408.
  9. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
  10. Latagliata R, Breccia M, Betrò P, Conte E, Aloe Spiriti A, D’Elia GM, Montefusco E, Rocchi L, Spadea A, Petti MC: A simple clinical scoring system in refractory anemia with excess of blasts in transformation. Leuk Res 1999;23(suppl 1):s178.
  11. Michels MD, Saumur J, Arthur DC, Robison LL, Brunning RD: Refractory anemia with excess of blasts in transformation: hematologic and clinical study of 52 patients. Cancer 1989;64:2340–2346.
  12. Seymour JF, Estey EH: The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes. Leuk Lymphoma 1995;17:79–85.
  13. Germing U, Strupp C, Giagounidis AS, Meckenstock G, Aul C: RAEB-t: a heterogenous entity. Leuk Res 1999;23(suppl 1):A169.
  14. Albitar M, Beran M, O’Brien S, Kantarjian H, Frierich E, Keating M, Estey E: Differences between refractory anemia with excess blasts in transformation and acute myeloid leukaemia. Blood 2000;96:372–373.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50